On July 1, 2026, women's pelvic-health company Materna Medical announced it had closed a $5 million "B3" financing round led by InnovaHealth Partners, Wavemaker360 Health, and Band of Angels, with continued participation from existing investors. The capital is earmarked to complete the readout of Materna's EASE pivotal trial — a large randomized controlled study running across 20 U.S. hospitals — plus commercial manufacturing buildout and launch prep for its lead device, the Ellora Obstetrical System.

Why It Matters

Most femtech capital chases fertility tracking, period care, and menopause; comparatively little flows to the unglamorous mechanics of birth injury, despite pelvic-floor dysfunction affecting a large share of first-time mothers and feeding directly into downstream sexual-health problems. A funded pivotal RCT plus an active reimbursement code is exactly the evidence-and-payment combination that has eluded most hardware-heavy femtech players (see Elvie's collapse), and it positions Materna as a rare "preventive pelvic health" story rather than another consumer gadget. For investors, the round is a data point that clinically validated, reimbursable women's-health devices — not just DTC wellness — remain fundable even in a tight market.

Ellora is an investigational device designed to reduce pelvic-floor muscle injury during vaginal delivery in first-time mothers, gently pre-stretching tissue to lower the risk of the tearing and levator-ani damage that childbirth so often causes. Materna says a first-in-class reimbursement code for the device is now active — an unusually concrete signal of commercial viability for a pre-launch women's-health product. President and CEO Tracy MacNeal framed the round as the runway to "the Ellora launch, bringing an important innovation to women's health."

The pelvic-floor angle is where this intersects the sexual-wellness beat directly. Injury sustained during childbirth is a leading driver of long-term urinary incontinence, pelvic organ prolapse, and sexual dysfunction — including pain during sex and diminished sensation — that can persist for years or decades. Materna's existing product, Milli, is an FDA-cleared expanding vaginal dilator sold over the counter since 2023 for vaginismus and painful sex; Ellora would extend the company's platform upstream, from treating pelvic-floor conditions after they appear to preventing the injury in the delivery room in the first place.

Sources

Update — 2026-07-12

Initial entry — story first created.